Impact

Reduce clinical trial burden and expand patient access to the best possible care

Expanding Patient Access

Altru Health System Increased Patient Enrollment from 4% to 11% of its Oncology Population Pre-screening increased from 10,200 annual patient visits within Altru Cancer Center to over 21,200 cancer patient visits across the health system

“Altru Health System historically enrolled four percent of our cancer patient population in clinical trials. Our partnership with Paradigm and our Research Department’s implementation of industry leading best practices increased this enrollment to 11% of the population. This has a profound impact on patients’ lives in a rural community that otherwise would not have access to clinical research as a care option."

Ashlee Dagoberg, PT, DPT
Manager of Research Program, Altru Health System

Increasing Patient Enrollment

Highlands Oncology Increased Clinical Trial Participation by 45% All patients under care at Highlands are now considered for clinical research as a care option alongside the best available standard of care throughout their treatment journey.

“Highlands has increased clinical trial patient enrollment by 45% over the last two years, while also reducing the burden on the research department. These accomplishments were achieved through the deployment of industry leading best practices, technology, and automations, including Paradigm, who has served as an invaluable partner for our research program.”

Adam Torres, BSBA, BSN, RN, CCRP
Director of Research Development, Highlands Oncology

Accelerating Global Trials

Paradigm Partners with Fujitsu to Solve Clinical Trials in Japan The collaboration reduces the administrative burden of clinical trial participation for Japanese hospitals, expands patient access, and provides global pharmaceutical companies with a streamlined path to world-class hospitals to accelerate the development of new therapies.

Improving Screening Accuracy

OpenAI Highlights Paradigm’s Innovative Use of GPT-4 to Improve Patient Access to Clinical Trials 10% more accurate than state of the art machine learning models in 90% less expert clinician time

“The accuracy of OpenAI was better than our existing deployment and optimization of industry best-practice expert-trained models, and it was sometimes better than our trained clinicians. The more complex the information, and the more different places that information sat, the better GPT-4 was.”

Jonathan Hirsch
Chief Strategy and Growth Officer, Paradigm

Connect with Us

Stay up to date with the latest Paradigm news, updates and information.